Juri Iwata, Masanori Yamamoto, Kei Kamata, Ryo Arita, T. Moriizumi, Toshinobu Ryuzaki, Hikaru Tsuruta, Takahiro Tokuda, Tetsuro Shimura, Shinichi Shirai, Kenichi Ishizu, Yusuke Watanabe, Toru Naganuma, Futoshi Yamanaka, Masahiko Noguchi, Yohei Ohno, Masaki Izumo, Hidetaka Nishina, Masahiko Asami, Gaku Nakazawa, Fumiaki Yashima, Hirofumi Hioki, Yasushi Fuku, Hiroto Suzuyama, Kazumasa Yamasaki, Kenji Nishioka, Daisuke Hachinohe, Toshiaki Otsuka, Norio Tada, Hideyuki Shimizu, Masaki Ieda, Kentaro Hayashida
BACKGROUND: The poor prognosis of hemodialysis (HD) patients following transcatheter aortic valve replacement (TAVR) has been established; however, data on the outcomes in the latest generation of devices remain inconsistent. OBJECTIVES: The authors aimed to compare the 1-year clinical outcomes post-TAVR using the latest generation of devices in HD and non-HD patients. METHODS: From the multicenter registry, 760 HD and 3,928 non-HD patients were identified from the OCEAN-TAVI (Optimized transCathEter vAlvular iNtervention-Transcatheter Aortic Valve Implantation; UMINID:000020423) registry. To minimize differences in baseline characteristics, 1:1 propensity score matching (PSM) was performed (490 patients each). The primary clinical endpoint was all-cause mortality at 1 year. Secondary endpoints included cardiovascular death, stroke, and heart failure rehospitalization. RESULTS: In the overall cohort, during 208 (41-373) days of follow-up, HD patients had higher 1-year mortality than non-HD patients (105 of 760 [13.8%] vs 189 of 3,928 [4.8%], HR: 2.62; 95% CI: 2.13-3.23; P < 0.001); this difference was attenuated (59 of 490 [12.0%] vs 65 of 490 [13.3%], HR: 1.03; 95% CI: 0.75-1.42; P = 0.858) following well-balanced PSM. There were no significant differences in any secondary endpoints between the 2 groups after PSM; however, HD remained an independent predictor of 1-year mortality in a multivariate analysis of the cohort before PSM. CONCLUSIONS: The poor prognostic value of HD was attenuated after adjusting for baseline risk factors. These findings suggest that the poor outcomes of HD patients result from the burden of multiple comorbidities in addition to the HD risk itself. Considering TAVR as a treatment option for exceptionally high-risk populations will aid in the careful patient selection and realistic prognostic assessments.